S&P 500   4,597.43 (-1.24%)
DOW   34,666.57 (-1.34%)
QQQ   395.00 (-1.17%)
AAPL   164.27 (+2.51%)
MSFT   332.17 (-1.32%)
FB   327.78 (-3.03%)
GOOGL   2,855.15 (-1.91%)
AMZN   3,513.63 (-1.35%)
TSLA   1,136.76 (-0.02%)
NVDA   325.29 (-2.54%)
BABA   127.18 (-3.37%)
NIO   39.21 (-3.09%)
CGC   10.50 (-5.06%)
AMD   158.29 (-2.24%)
GE   95.48 (-2.97%)
MU   85.23 (-1.06%)
T   22.73 (-4.86%)
F   19.25 (-2.14%)
DIS   144.40 (-2.31%)
ACB   6.27 (-2.64%)
AMC   34.23 (-7.08%)
PFE   54.17 (+3.38%)
BA   195.95 (-1.28%)
S&P 500   4,597.43 (-1.24%)
DOW   34,666.57 (-1.34%)
QQQ   395.00 (-1.17%)
AAPL   164.27 (+2.51%)
MSFT   332.17 (-1.32%)
FB   327.78 (-3.03%)
GOOGL   2,855.15 (-1.91%)
AMZN   3,513.63 (-1.35%)
TSLA   1,136.76 (-0.02%)
NVDA   325.29 (-2.54%)
BABA   127.18 (-3.37%)
NIO   39.21 (-3.09%)
CGC   10.50 (-5.06%)
AMD   158.29 (-2.24%)
GE   95.48 (-2.97%)
MU   85.23 (-1.06%)
T   22.73 (-4.86%)
F   19.25 (-2.14%)
DIS   144.40 (-2.31%)
ACB   6.27 (-2.64%)
AMC   34.23 (-7.08%)
PFE   54.17 (+3.38%)
BA   195.95 (-1.28%)
S&P 500   4,597.43 (-1.24%)
DOW   34,666.57 (-1.34%)
QQQ   395.00 (-1.17%)
AAPL   164.27 (+2.51%)
MSFT   332.17 (-1.32%)
FB   327.78 (-3.03%)
GOOGL   2,855.15 (-1.91%)
AMZN   3,513.63 (-1.35%)
TSLA   1,136.76 (-0.02%)
NVDA   325.29 (-2.54%)
BABA   127.18 (-3.37%)
NIO   39.21 (-3.09%)
CGC   10.50 (-5.06%)
AMD   158.29 (-2.24%)
GE   95.48 (-2.97%)
MU   85.23 (-1.06%)
T   22.73 (-4.86%)
F   19.25 (-2.14%)
DIS   144.40 (-2.31%)
ACB   6.27 (-2.64%)
AMC   34.23 (-7.08%)
PFE   54.17 (+3.38%)
BA   195.95 (-1.28%)
S&P 500   4,597.43 (-1.24%)
DOW   34,666.57 (-1.34%)
QQQ   395.00 (-1.17%)
AAPL   164.27 (+2.51%)
MSFT   332.17 (-1.32%)
FB   327.78 (-3.03%)
GOOGL   2,855.15 (-1.91%)
AMZN   3,513.63 (-1.35%)
TSLA   1,136.76 (-0.02%)
NVDA   325.29 (-2.54%)
BABA   127.18 (-3.37%)
NIO   39.21 (-3.09%)
CGC   10.50 (-5.06%)
AMD   158.29 (-2.24%)
GE   95.48 (-2.97%)
MU   85.23 (-1.06%)
T   22.73 (-4.86%)
F   19.25 (-2.14%)
DIS   144.40 (-2.31%)
ACB   6.27 (-2.64%)
AMC   34.23 (-7.08%)
PFE   54.17 (+3.38%)
BA   195.95 (-1.28%)
NASDAQ:KTTA

Pasithea Therapeutics Stock Forecast, Price & News

$3.57
-0.68 (-16.00%)
(As of 11/30/2021 02:03 PM ET)
Add
Compare
Today's Range
$3.36
▼
$4.43
50-Day Range
$2.21
▼
$5.60
52-Week Range
$2.10
▼
$8.50
Volume
61,526 shs
Average Volume
11.25 million shs
Market Capitalization
$47.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive KTTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Pasithea Therapeutics

Pasithea Therapeutics Corp. is a biotechnology company. It focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Pasithea Therapeutics Corp. is based in MIAMI BEACH, Fla.

Headlines

Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
November 29, 2021 |  finance.yahoo.com
Pasithea Therapeutics Corp Shares Close the Week 66.3% Higher - Weekly Wrap
November 27, 2021 |  nasdaq.com
Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
November 24, 2021 |  finance.yahoo.com
5 Top Stock Gainers for Tuesday Climb After Powell Renomination
November 23, 2021 |  finance.yahoo.com
Mid-Day Market Update: Nasdaq Tumbles Over 200 Points; Pasithea Therapeutics Shares Surge
November 23, 2021 |  markets.businessinsider.com
EXCLUSIVE: Pasithea's Depression Treatment, Esketamine Nasal Spray Added In Clinic Offerings In UK
November 23, 2021 |  msn.com
Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.
November 23, 2021 |  finance.yahoo.com
Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint
November 17, 2021 |  finance.yahoo.com
EXCLUSIVE: Pasithea Clinics Launches In-Home Intravenous Ketamine Therapy In Major US Cities
November 17, 2021 |  benzinga.com
Biotech Company Pasithea Therapeutics Founders on Entrepreneurship in Science
November 15, 2021 |  finance.yahoo.com
Pasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy
November 11, 2021 |  au.finance.yahoo.com
Pasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair
November 9, 2021 |  finance.yahoo.com
Pasithea Therapeutics Corp
October 29, 2021 |  reuters.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KTTA
Previous Symbol
CUSIP
N/A
CIK
1841330
Web
www.pasithea.com
Phone
702-514-4174
Fax
N/A
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
13,210,000
Free Float
N/A
Market Cap
$47.16 million
Optionable
Not Optionable

Company Calendar

Today
11/30/2021
Fiscal Year End
12/31/2021

MarketRank™

Overall MarketRank™

0.45 out of 5 stars

Medical Sector

1326th out of 1,390 stocks

Pharmaceutical Preparations Industry

645th out of 669 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Pasithea Therapeutics (NASDAQ:KTTA) Frequently Asked Questions

When did Pasithea Therapeutics IPO?

(KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

What is Pasithea Therapeutics' stock symbol?

Pasithea Therapeutics trades on the NASDAQ under the ticker symbol "KTTA."

When did the company's quiet period expire?

Pasithea Therapeutics' quiet period expired on Monday, October 25th. Pasithea Therapeutics had issued 4,800,000 shares in its public offering on September 15th. The total size of the offering was $24,000,000 based on an initial share price of $5.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Pasithea Therapeutics' major shareholders?

Pasithea Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Two Sigma Securities LLC (0.08%).

Which institutional investors are buying Pasithea Therapeutics stock?

KTTA stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Securities LLC.

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pasithea Therapeutics' stock price today?

One share of KTTA stock can currently be purchased for approximately $3.57.

How much money does Pasithea Therapeutics make?

Pasithea Therapeutics has a market capitalization of $47.16 million.

How many employees does Pasithea Therapeutics have?

Pasithea Therapeutics employs 2 workers across the globe.

What is Pasithea Therapeutics' official website?

The official website for Pasithea Therapeutics is www.pasithea.com.

Where are Pasithea Therapeutics' headquarters?

Pasithea Therapeutics is headquartered at 1111 Lincoln Road Suite 500, Miami Beach FL, 33139.

How can I contact Pasithea Therapeutics?

Pasithea Therapeutics' mailing address is 1111 Lincoln Road Suite 500, Miami Beach FL, 33139. The company can be reached via phone at 702-514-4174 or via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.